Why the study?
TNF-alpha plays a vital role in hypertension pathogenesis and its inhibitors improve clinical symptoms, but their outcome on high blood pressure has not been investigated.
Are serum levels of TNF-α, MDA, and FRAP altered in patients with hypertension compared to healthy controls?
Case-Control (n=60)
Are serum levels of TNF-α, MDA, and FRAP altered in patients with hypertension compared to healthy controls?
Hypertension is associated with increased oxidative stress and inflammation, evidenced by elevated TNF-α and MDA levels and decreased antioxidant capacity.
Supports oxidative-inflammatory pathways in hypertension; hypothesis-generating for targeted interventions.
Background: Concurrent with the imbalance of oxidizing agents and antioxidants, high blood pressure (BP) is a major physical condition burden in the current scenario. Tumor necrosis factor-alpha (TNF-α) plays a vital role in the pathogenesis of hypertension (HTN). TNF-α inhibitor improves clinical symptoms; however, their outcome on high BP has not been investigated. We investigated the inflammatory marker TNF-α, malondialdehyde (MDA), and ferric reducing antioxidant power (FRAP) in hypertensive patients. We measured BP randomly using an ambulatory observe in hypertensive patients. Measured systolic BP was 140 mmHg and/or diastolic BP was 90 mmHg were considered hypertensive. Materials and Methods: A total of 60 cases were considered in the study involving 30 hypertensive patients and 30 normal controls (30). Measurements of serum concentrations of TNF-α, MDA, and FRAP in HTN patients were done in both the groups. Results: Serum TNF-α was found to be remarkably increased in study participants as compared to the normal group (r = 0.32,P < 0.0001*). Serum MDA was also raised in hypertensive as compared to the control group (r = 0.99**,P < 0.0001*), whereas serum FRAP was found to be decreased in the hypertensive group in comparison to the healthy controls (r = 0.23,P < 0.0001*). Conclusions: It is concluded that high BP leads to the generation of oxidative stress with a remarkable elevation of TNF-α and MDA levels. The indicates decrease level of Ferric Reducing Antioxidant Power (FRAP) and suggest a possible role of oxidative stress in the pathophysiology of hypertension.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2019) conducted a case-control in Hypertension (n=60). Hypertension vs. Healthy controls was evaluated on Serum concentrations of TNF-α, MDA, and FRAP (p=<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: